Keyphrases
Hyperglycemia
100%
Type 2 Diabetic Patients
100%
Evidence-based Treatment
100%
Kidney Disease Progression
100%
Incretin-based Therapy
100%
Chronic Kidney Disease
42%
Glycemic Control
42%
Cardiovascular Risk
28%
Clinical Trials
14%
Comorbidity
14%
Number of Patients
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Treatment Regimen
14%
Receptor Agonist
14%
Patient Demographics
14%
Glucagon-like
14%
Treatment Strategy
14%
A1 Receptor
14%
Pharmacotherapy
14%
Cardiovascular Therapy
14%
Evidence Support
14%
Diabetes Management
14%
Glucose-lowering Drugs
14%
Disease Treatment
14%
Clinical Trial Data
14%
End-stage Kidney Disease
14%
Individualized Approach
14%
Disease Categories
14%
Optimal Strategy
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Concomitant Therapy
14%
Growing Patients
14%
Medicine and Dentistry
Hyperglycemia
100%
Patient with Type 2 Diabetes
100%
Chronic Kidney Disease
100%
Incretin
100%
Clinical Trial
20%
Glycemic Control
20%
Cardiovascular System
10%
Drug Therapy
10%
Prevalence
10%
Diabetes
10%
Maturity Onset Diabetes of the Young
10%
Cardiovascular Disease
10%
End Stage Renal Disease
10%
Patient Population
10%
Glycemic
10%
Glucagon-Like Peptide-1 Agonist
10%
Cardiovascular Disease Treatment
10%
Dipeptidyl Peptidase-4 Inhibitor
10%
Comorbidity
10%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperglycemia
100%
Chronic Kidney Failure
100%
Incretin
100%
Maturity Onset Diabetes of the Young
100%
Clinical Trial
20%
Cardiovascular Disease
20%
Combination Therapy
10%
Prevalence
10%
Pharmacotherapy
10%
End Stage Renal Disease
10%
Glucagon Like Peptide 1 Receptor Agonist
10%
Dipeptidyl Peptidase IV Inhibitor
10%
Comorbidity
10%